Patients with juvenile idiopathic arthritis (JIA) commonly experience ocular complications and vision loss. As uveitis activity increases, so does the risk for vision loss. A new study confirms that the use of immunosuppressive drugs is associated with a reduced risk of vision loss in patients with JIA-related uveitis.1 New data also indicate that the use of immunosuppressive drugs in this patient population decreases the risk of the patient’s visual acuity (VA) dropping below the 20/50 thresholds.
You Might Also Like
Also By This Author
The study was performed by Anthony C. Gregory II, MD, MPH, and Jennifer E. Thorne, MD, PhD, at Johns Hopkins University School of Medicine in Baltimore, who worked with the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group to examine a large retrospective cohort of patients with JIA-associated uveitis. The study included 327 children from five tertiary-care uveitis clinics. The children were relatively young at the age of JIA diagnosis (median age=4.1 years; range, 4 months to 16.9 years).
The investigators measured inflammation and vision loss. Specifically, they identified the presence of posterior synechiae, active anterior chamber inflammation, previous intraocular surgery, and vision loss across two VA thresholds (≤20/50 and ≤20/200). They found that posterior synechiae, active uveitis, and prior intraocular surgery were all statistically significantly associated with both VA thresholds at presentation and during follow-up.
Previously, studies have shown that the use of immunosuppressive drugs is associated with a reduced risk of at least moderate visual loss. The current study confirmed these results. The authors also found that the eyes of patients who had not developed ocular complications before presentation to the ophthalmology clinics were significantly less likely to develop ocular complications during follow-up visits.
Most eyes, however, were affected at presentation: 40.3% had a VA of ≤20/50, 24.2% had a VA of ≤20/200, and 60.2% had at least one ocular complication. The incidence of VA loss to the ≤20/50 threshold was 0.18 per eye-year (EY) and 0.09 per EY to the ≤20/200 threshold. The investigators calculated the incidence of developing at least one new ocular complication over follow-up as 0.15/EY.
Patients who had uveitis but whose eyes did not have complications at presentation had a 0.04/EY rate of developing at least one ocular complication during follow-up.
Increasing anterior chamber cell grade was associated with a dose-dependent increase in visual loss. In particular, active uveitis was associated with loss of VA for anterior chamber cell levels of 1+ or higher. Although the reduction in VA may be reversible in some cases, the authors assumed, when calculating risk of vision loss from uveitis, that the eyes never recover VA.